Company Filing History:
Years Active: 2025
Title: Innovations in Cancer Treatment by Steven O'Neil
Introduction
Steven O'Neil is a notable inventor based in Wayland, MA (US). He has made significant contributions to the field of cancer treatment through his innovative work in multi-specific binding proteins. With a total of 4 patents, O'Neil's inventions focus on advanced therapeutic methods that target cancer cells effectively.
Latest Patents
O'Neil's latest patents include groundbreaking developments in multi-specific binding proteins that bind to B-cell maturation antigen (BCMA), NKG2D, and CD16. These proteins are designed to bind to and kill human cancer cells, providing new pharmaceutical compositions and therapeutic methods for treating cancers that express BCMA. His research demonstrates that these multi-specific binding proteins exhibit high potency and maximum lysis of target cells compared to traditional anti-BCMA monoclonal antibodies. Additionally, he has developed proteins that bind to the NKG2D receptor, CD16, and various tumor-associated antigens, further enhancing the potential for effective cancer treatments.
Career Highlights
O'Neil is currently associated with Dragonfly Therapeutics, Inc., where he continues to innovate in the field of cancer therapeutics. His work has positioned him as a key figure in the development of novel treatments that leverage the body's immune response to combat cancer.
Collaborations
Some of O'Neil's notable coworkers include Gregory P. Chang and Ann F. Cheung, who contribute to the collaborative efforts in advancing cancer treatment technologies.
Conclusion
Steven O'Neil's contributions to cancer treatment through his innovative patents highlight the potential of multi-specific binding proteins in modern medicine. His work continues to pave the way for new therapeutic approaches that could significantly improve patient outcomes.